Shionogi plans to acquire global rights to Radicava and Radicava ORS for ALS through a new U.S. business formed by Tanabe ...

Disease progression in amyotrophic lateral sclerosis (ALS) patients who received edaravone (Radicava) plus standard therapy of riluzole (Rilutek) did not differ from patients treated with standard ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

Review the side-effects of Edaravone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Edaravone (Aravon) is prescribed for treating ...

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger that has shown potent antioxidant, anti-inflammatory and neuroprotective effects in variety of disease models. In this study ...

Edaravone, a medication that scrubs cells of toxic free radicals, may help a subset of people with amyotrophic lateral sclerosis. That was the upshot of a presentation at the International Symposium ...

Both on/off dosing and daily oral edaravone led to similar scores (P=0.777) on the Combined Assessment of Function and Survival (CAFS) at week 48, reported Jeffrey Rothstein, MD, PhD, of Johns Hopkins ...

The US Food and Drug Administration has approved the first new drug for the treatment of amyotrophic lateral sclerosis, or ALS, in more than two decades. The FDA announced Friday that Radicava, also ...

Oral edaravone for patients with amyotrophic lateral sclerosis (ALS) is safe through a total of 144 weeks with no new safety signals observed. Among patients with amyotrophic lateral sclerosis (ALS), ...

Oral edaravone was developed to have a similar clinical profile as the intravenous formulation Radicava. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...